Compare Citius Pharmaceuticals Inc (CTXR) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Marriott International Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Marriott International Inc trades at $349.5 (market cap $90.86B). The key difference: Marriott International Inc is far larger — about 4851× Citius Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MAR | |
|---|---|---|
Market Cap | $18.73M | $90.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $402.54 |
52-Week Low | $0.48 | $259.04 |
Enterprise Value | $14.95M | $108.17B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Marriott International (MAR) trades at $353.91, down 1.6% in the last 24 hours, with a bearish technical signal. The stock shows strong profitability with a net income margin of 9.62% and ROE of 1,446.77%, but faces high valuation ratios like a P/E of 36.64. Recent Q2 2026 earnings beat estimates at $3.19 per share, and the company raised its 2026 outlook, though revenue missed expectations. A quarterly dividend of $0.73 per share was declared, payable on June 30, 2026.
The outlook is mixed: robust fee growth and a record pipeline support upside, but elevated debt and premium valuation pose risks. Analysts are generally positive with a consensus price target of $387.31, though near-term volatility may persist due to macroeconomic headwinds and regional weaknesses in the Middle East.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
